Response to Ansell et al. “Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel”

Thromb Haemost 2014; 112(04): 842
DOI: 10.1160/TH14-06-0564

Author Correspondence

Schattauer GmbH

Steen Husted

¹Medical Department, Hospital Unit West, Herning, Denmark

,

Gregory Y. H. Lip

²University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK

,

the ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease

References
1 Ansell J, Crowther M, Burnett A. et al. Letter to the Editor. Thromb Haemost 2014; 112: 841.
2 Lip GYH, Camm J, Hylek EM. et al. Non-vitamin K antagonist oral anticoagulants. An appeal for concensus on terminology. Chest 2014; 145: 1177-1178.
3 Majeed A, Hwang HG, Connolly SJ. et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 2013; 128: 2325-2332.
4 De Caterina R, Husted S, Wallentin L. et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 110: 1087-1107.
5 De Caterina R, Husted S, Wallentin L. et al. European Society of Cardiology Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 109: 569-579.